Autolus Therapeutics Archives

Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

LONDON, Jun. 26 (Korea Bizwire) – Autolus Therapeutics plc (“Autolus”) (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced initial public offering in the United States of 10,147,059 American Depositary Shares (“ADSs”), representing 10,147,059 ordinary shares, at an initial public offering price of $17.00 [...]

Autolus Announces Pricing of Initial Public Offering

LONDON, Jun. 22 (Korea Bizwire) – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530 ordinary shares at an initial public offering price of $17.00 per ADS for total [...]